IGLON5 and movement disorder: As there is already some evidence for response to early immunotherapy,13, 15, 30, 31 we suggest that the indication for anti‐IgLON5 antibody screening should be extended and considered in patients even when sleep‐related symptoms are not present, especially when they present with bulbar symptoms, movement disorders, or neurocognitive impairment.